Temat: "Interleukin-6" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: The persistence of interleukin-6 is regulated by a blood buffer system derived from dendritic cells.
Autorzy :: Yousif AS; The Ragon Institute of Massachusetts General Hospital, The Massachusetts Institute of Technology and Harvard University, 400 Technology Square, Cambridge, MA 02139, USA.
Ronsard L; The Ragon Institute of Massachusetts General Hospital, The Massachusetts Institute of Technology and Harvard University, 400 Technology Square, Cambridge, MA 02139, USA.
Shah P; The Center for the Study of Inflammatory Bowel Disease, Center for Computational and Integrative Biology, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, USA.
Omatsu T; The Center for the Study of Inflammatory Bowel Disease, Center for Computational and Integrative Biology, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, USA.
Sangesland M; The Ragon Institute of Massachusetts General Hospital, The Massachusetts Institute of Technology and Harvard University, 400 Technology Square, Cambridge, MA 02139, USA.
Bracamonte Moreno T; The Ragon Institute of Massachusetts General Hospital, The Massachusetts Institute of Technology and Harvard University, 400 Technology Square, Cambridge, MA 02139, USA.
Lam EC; The Ragon Institute of Massachusetts General Hospital, The Massachusetts Institute of Technology and Harvard University, 400 Technology Square, Cambridge, MA 02139, USA.
Vrbanac VD; The Ragon Institute of Massachusetts General Hospital, The Massachusetts Institute of Technology and Harvard University, 400 Technology Square, Cambridge, MA 02139, USA.
Balazs AB; The Ragon Institute of Massachusetts General Hospital, The Massachusetts Institute of Technology and Harvard University, 400 Technology Square, Cambridge, MA 02139, USA.
Reinecker HC; The Center for the Study of Inflammatory Bowel Disease, Center for Computational and Integrative Biology, Massachusetts General Hospital, 185 Cambridge Street, Boston, MA 02114, USA; The Center for the Genetics of Host Defense, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390, USA.
Lingwood D; The Ragon Institute of Massachusetts General Hospital, The Massachusetts Institute of Technology and Harvard University, 400 Technology Square, Cambridge, MA 02139, USA. Electronic address: .; Pokaż więcej
Źródło :: Immunity [Immunity] 2021 Feb 09; Vol. 54 (2), pp. 235-246.e5. Date of Electronic Publication: 2020 Dec 22.
Typ publikacji :: Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :: Dendritic Cells/*immunology
Interleukin-6/*blood
Interleukin-6/*immunology
ADAM17 Protein ; Animals ; Cell Differentiation ; Immunity, Humoral ; Immunoglobulin M/immunology ; Inflammation ; Interferon Regulatory Factors/genetics ; Interferon Regulatory Factors/immunology ; Interleukin-6/genetics ; Membrane Glycoproteins/immunology ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Plasma Cells/immunology ; Receptors, Interleukin-6/blood ; Receptors, Interleukin-6/immunology ; Signal Transduction/immunology ; Toll-Like Receptor 4/immunology ; Toll-Like Receptor 7/immunology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Serum Concentrations of Interleukin 6 in the General Adult Population: Possible Implications for Anti-IL-6 Therapy in SARS-Cov-2 Infection and IL-6-Related Diseases.
Autorzy :: Alende-Castro V; Department of Internal Medicine, Complejo Hospitalario Universitario, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Alonso-Sampedro M; Department of Clinical Epidemiology, Complejo Hospitalario Universitario, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Gude F; Department of Clinical Epidemiology, Complejo Hospitalario Universitario, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
Gonzalez-Quintela A; Department of Internal Medicine, Complejo Hospitalario Universitario, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.; Pokaż więcej
Źródło :: Journal of investigational allergology & clinical immunology [J Investig Allergol Clin Immunol] 2021 Feb 17; Vol. 31 (1), pp. 75-78. Date of Electronic Publication: 2020 Jun 05.
Typ publikacji :: Journal Article
MeSH Terms :: COVID-19/*blood
Interleukin-6/*blood
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/therapeutic use ; Biomarkers/blood ; COVID-19/diagnosis ; COVID-19/drug therapy ; COVID-19/immunology ; Cross-Sectional Studies ; Female ; Humans ; Immunologic Factors/therapeutic use ; Interleukin-6/antagonists & inhibitors ; Male ; Middle Aged ; Receptors, Interleukin-6/antagonists & inhibitors ; Reference Values ; Up-Regulation ; Young Adult
SCR Protocol :: COVID-19 drug treatment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19.
Autorzy :: Khaedir Y; Department of Histology, Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, Indonesia.; Immunology, Master's Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, Indonesia.
Kartika R; Division of Metabolic, Endocrinology, and Diabetes, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, Indonesia.; Pokaż więcej
Źródło :: Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research [J Interferon Cytokine Res] 2021 Feb; Vol. 41 (2), pp. 37-43.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :: COVID-19/*pathology
Receptors, Interleukin-6/*antagonists & inhibitors
Respiratory Distress Syndrome/*drug therapy
SARS-CoV-2/*immunology
Antibodies, Monoclonal, Humanized/therapeutic use ; COVID-19/drug therapy ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/pathology ; Cytokine Release Syndrome/prevention & control ; Humans ; Indonesia ; Interleukin-6/immunology ; Janus Kinase 1/antagonists & inhibitors ; Janus Kinase 2/antagonists & inhibitors ; Janus Kinase Inhibitors/therapeutic use ; Pyrazoles/therapeutic use ; SARS-CoV-2/drug effects ; Signal Transduction/immunology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 4 4.

Tytuł :: Audio Interview: A New SARS-CoV-2 Vaccine and a New Look at Treatment.
Autorzy :: Rubin EJ
Baden LR
Morrissey S; Pokaż więcej
Źródło :: The New England journal of medicine [N Engl J Med] 2021 Mar 04; Vol. 384 (9), pp. e46.
Typ publikacji :: Editorial; Interview
MeSH Terms :: COVID-19 Vaccines*/administration & dosage
COVID-19 Vaccines*/immunology
Antibodies, Monoclonal, Humanized/*therapeutic use
COVID-19/*drug therapy
COVID-19/*prevention & control
Immunologic Factors/*therapeutic use
Receptors, Interleukin-6/*antagonists & inhibitors
SARS-CoV-2/*genetics
Adenoviridae ; Genetic Variation ; Genetic Vectors ; Humans ; Interleukin-6/immunology ; Treatment Outcome ; Vaccine Potency
SCR Protocol :: COVID-19 drug treatment
: Opinia redakcyjna

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Can aldosterone increase interleukin-6 levels in Covid-19 pneumonia?
Autorzy :: Campana P; Department of Translational Medical Sciences, University Federico II, Naples, Italy.
Flocco V; Department of Translational Medical Sciences, University Federico II, Naples, Italy.
Aruta F; Department of Neuroscience, University Federico II, Naples, Italy.
Cacciatore F; Department of Translational Medical Sciences, University Federico II, Naples, Italy.
Abete P; Department of Translational Medical Sciences, University Federico II, Naples, Italy.; Pokaż więcej
Źródło :: Journal of medical virology [J Med Virol] 2021 Feb; Vol. 93 (2), pp. 622-623. Date of Electronic Publication: 2020 Aug 25.
Typ publikacji :: Case Reports; Letter
MeSH Terms :: Aldosterone/*blood
COVID-19/*immunology
Cytokine Release Syndrome/*immunology
Interleukin-6/*blood
COVID-19/complications ; COVID-19/diagnosis ; Female ; Guillain-Barre Syndrome/etiology ; Humans ; Middle Aged ; Receptors, Interleukin-6/blood
: Raport

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
Autorzy :: Antwi-Amoabeng D; Reno School of Medicine, University of Nevada, Reno, Nevada.; U.S. Department of Veterans Affairs, VA Sierra Nevada Health Care Systems, Reno, Nevada.
Kanji Z; Reno School of Medicine, University of Nevada, Reno, Nevada.; U.S. Department of Veterans Affairs, VA Sierra Nevada Health Care Systems, Reno, Nevada.
Ford B; Reno School of Medicine, University of Nevada, Reno, Nevada.; U.S. Department of Veterans Affairs, VA Sierra Nevada Health Care Systems, Reno, Nevada.
Beutler BD; Reno School of Medicine, University of Nevada, Reno, Nevada.; U.S. Department of Veterans Affairs, VA Sierra Nevada Health Care Systems, Reno, Nevada.
Riddle MS; Reno School of Medicine, University of Nevada, Reno, Nevada.; U.S. Department of Veterans Affairs, VA Sierra Nevada Health Care Systems, Reno, Nevada.
Siddiqui F; Reno School of Medicine, University of Nevada, Reno, Nevada.; U.S. Department of Veterans Affairs, VA Sierra Nevada Health Care Systems, Reno, Nevada.; Pokaż więcej
Źródło :: Journal of medical virology [J Med Virol] 2020 Nov; Vol. 92 (11), pp. 2516-2522. Date of Electronic Publication: 2020 Jun 09.
Typ publikacji :: Journal Article; Systematic Review
MeSH Terms :: Hospital Mortality*
Antibodies, Monoclonal, Humanized/*therapeutic use
COVID-19/*therapy
Interleukin-6/*antagonists & inhibitors
COVID-19/immunology ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/therapy ; Female ; Humans ; Interleukin-6/immunology ; Male ; Observational Studies as Topic ; Receptors, Interleukin-6/antagonists & inhibitors ; Severity of Illness Index ; Time Factors ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 7 7.

Tytuł :: Interleukin-6 receptor blocking with intravenous tocilizumab in COVID-19 severe acute respiratory distress syndrome: A retrospective case-control survival analysis of 128 patients.
Autorzy :: Canziani LM; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; Internal Medicine, Humanitas Gavazzeni, Bergamo (BG), Italy.
Trovati S; Internal Medicine, Humanitas Gavazzeni, Bergamo (BG), Italy.
Brunetta E; General Medicine and Nephrology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Testa A; Internal Medicine, Humanitas Gavazzeni, Bergamo (BG), Italy.
De Santis M; Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Bombardieri E; Scientific Direction, Humanitas Gavazzeni, Bergamo (BG), Italy.
Guidelli G; Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Albano G; Anesthesiology and Intensive Care, Humanitas Gavazzeni, Bergamo (BG), Italy.
Folci M; General Medicine and Hepatology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Squadroni M; Medical Oncology, Humanitas Gavazzeni, Bergamo (BG), Italy.
Beretta GD; Medical Oncology, Humanitas Gavazzeni, Bergamo (BG), Italy.
Ciccarelli M; General Medicine and Pulmonology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Castoldi M; Medical Direction, Humanitas Gavazzeni, Bergamo (BG), Italy.
Lleo A; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; General Medicine and Hepatology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Aghemo A; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; General Medicine and Hepatology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Vernile L; Pharmacy, Humanitas Gavazzeni, Bergamo (BG), Italy.
Malesci A; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; General Medicine and Gastroenterology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Omodei P; General Medicine and Gastroenterology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Angelini C; General Medicine and Nephrology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Badalamenti S; General Medicine and Nephrology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy.
Cecconi M; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; Anesthesiology andIntensive Care, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy. Electronic address: .
Cremonesi A; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; Cardiology, Humanitas Gavazzeni, Bergamo (BG), Italy.
Selmi C; Humanitas University, Department of Biomedical Sciences, Pieve Emanuele (MI), Italy; Rheumatology and Clinical Immunology, Humanitas Clinical and Research Center- IRCCS, Rozzano (MI), Italy. Electronic address: .; Pokaż więcej
Corporate Authors :: Humanitas and Gavazzeni / Castelli COVID-19 Task Forces
Źródło :: Journal of autoimmunity [J Autoimmun] 2020 Nov; Vol. 114, pp. 102511. Date of Electronic Publication: 2020 Jul 08.
Typ publikacji :: Journal Article
MeSH Terms :: Antibodies, Monoclonal, Humanized/*administration & dosage
Coronavirus Infections/*drug therapy
Pneumonia, Viral/*drug therapy
Receptors, Interleukin-6/*antagonists & inhibitors
Respiratory Distress Syndrome/*drug therapy
Aged ; Betacoronavirus/immunology ; COVID-19 ; Case-Control Studies ; Coronavirus Infections/complications ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Female ; Hospital Mortality ; Humans ; Infusions, Intravenous ; Interleukin-6/immunology ; Interleukin-6/metabolism ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; Receptors, Interleukin-6/metabolism ; Respiratory Distress Syndrome/diagnosis ; Respiratory Distress Syndrome/immunology ; Respiratory Distress Syndrome/mortality ; Retrospective Studies ; SARS-CoV-2 ; Severity of Illness Index ; Survival Analysis ; Treatment Outcome
SCR Protocol :: COVID-19 drug treatment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: Interleukin-6 Receptor Asp358 A>C Polymorphism Is Associated With Postoperative Atrial Fibrillation.
Autorzy :: Wu F; Department of Adult Nursing, Department of Adult Nursing, School of Nursing, Capital Medical University, Beijing, China. Electronic address: .
Feng X; Department of Adult Nursing, Department of Adult Nursing, School of Nursing, Capital Medical University, Beijing, China.
Wu Y; Department of Adult Nursing, Department of Adult Nursing, School of Nursing, Capital Medical University, Beijing, China.
Yu M; Department of Adult Nursing, Department of Adult Nursing, School of Nursing, Capital Medical University, Beijing, China.
Ding S; Cardiac Center, Cardiac Center, Beijing Chao-yang Hospital Affiliated With Capital Medical University, Beijing, China.
Zhao H; Cardiac Center, Cardiac Center, Beijing Chao-yang Hospital Affiliated With Capital Medical University, Beijing, China.; Pokaż więcej
Źródło :: The Annals of thoracic surgery [Ann Thorac Surg] 2021 Jan; Vol. 111 (1), pp. 102-108. Date of Electronic Publication: 2020 Jun 17.
Typ publikacji :: Journal Article
MeSH Terms :: Coronary Artery Bypass*
Polymorphism, Single Nucleotide*
Atrial Fibrillation/*genetics
Postoperative Complications/*genetics
Receptors, Interleukin-6/*genetics
Aged ; Atrial Fibrillation/blood ; Female ; Genotype ; Humans ; Interleukin-6/blood ; Male ; Middle Aged ; Postoperative Complications/blood ; Prospective Studies
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: Autocrine IL-6/STAT3 signaling aids development of acquired drug resistance in Group 3 medulloblastoma.
Autorzy :: Sreenivasan L; Department of Medicine, University of British Columbia, Vancouver, BC, Canada.; Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Wang H; Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.; Department of Microbiology and Immunology, Jinan University, Guangzhou, People's Republic of China.
Yap SQ; Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
Leclair P; Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada.; Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
Tam A; Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada.
Lim CJ; Michael Cuccione Childhood Cancer Research Program, BC Children's Hospital Research Institute, Vancouver, BC, Canada. .; Department of Pediatrics, University of British Columbia, Vancouver, BC, Canada. .; Pokaż więcej
Źródło :: Cell death & disease [Cell Death Dis] 2020 Dec 05; Vol. 11 (12), pp. 1035. Date of Electronic Publication: 2020 Dec 05.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Autocrine Communication*/drug effects
Autocrine Communication*/genetics
Drug Resistance, Neoplasm*/genetics
Signal Transduction*/drug effects
Brain Neoplasms/*drug therapy
Brain Neoplasms/*metabolism
Interleukin-6/*metabolism
Medulloblastoma/*drug therapy
Medulloblastoma/*metabolism
STAT3 Transcription Factor/*metabolism
Cell Line, Tumor ; Cisplatin/pharmacology ; Cisplatin/therapeutic use ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Medulloblastoma/genetics ; Medulloblastoma/pathology ; Niclosamide/pharmacology ; Niclosamide/therapeutic use ; Receptors, Interleukin-6/metabolism ; Vincristine/pharmacology ; Vincristine/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease.
Autorzy :: Samaee H; Departement of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Mohsenzadegan M; Department of Medical Laboratory Sciences, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
Ala S; Departement of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Maroufi SS; Departemernt of Anesthsia, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran.
Moradimajd P; Departemernt of Anesthsia, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran. Electronic address: .; Pokaż więcej
Źródło :: International immunopharmacology [Int Immunopharmacol] 2020 Dec; Vol. 89 (Pt A), pp. 107018. Date of Electronic Publication: 2020 Sep 16.
Typ publikacji :: Journal Article; Review
MeSH Terms :: SARS-CoV-2*
Antibodies, Monoclonal, Humanized/*therapeutic use
COVID-19/*drug therapy
Receptors, Interleukin-6/*antagonists & inhibitors
Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal, Humanized/pharmacology ; COVID-19/complications ; Humans ; Interleukin-6/physiology
SCR Protocol :: COVID-19 drug treatment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Expression of Interleukin 6 signaling receptors in carotid atherosclerosis.
Autorzy :: Ziegler L; Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.; Department of Medicine, Danderyd Hospital, Stockholm, Sweden.
Lundqvist J; Cardiovascular Medicine Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Dreij K; Unit of Biochemical Toxicology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Wallén H; Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.; Department of Cardiology, Danderyd Hospital, Stockholm, Sweden.
de Faire U; Unit of Cardiovascular and Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.; Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
Paulsson-Berne G; Cardiovascular Medicine Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
Hedin U; Department of Vascular Surgery, Karolinska University Hospital, Stockholm, Sweden.; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Matic L; Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Gigante B; Cardiovascular Medicine Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.; Department of Cardiology, Danderyd Hospital, Stockholm, Sweden.; Pokaż więcej
Źródło :: Vascular medicine (London, England) [Vasc Med] 2021 Feb; Vol. 26 (1), pp. 3-10. Date of Electronic Publication: 2020 Dec 22.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Plaque, Atherosclerotic*
Carotid Arteries/*metabolism
Carotid Stenosis/*metabolism
Cytokine Receptor gp130/*metabolism
Interleukin-6/*metabolism
Receptors, Interleukin-6/*metabolism
Aged ; Biomarkers/metabolism ; Carotid Arteries/surgery ; Carotid Stenosis/blood ; Carotid Stenosis/genetics ; Carotid Stenosis/therapy ; Cross-Sectional Studies ; Cytokine Receptor gp130/blood ; Cytokine Receptor gp130/genetics ; Endarterectomy, Carotid ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Interleukin-6/blood ; Interleukin-6/genetics ; Male ; Receptors, Interleukin-6/blood ; Receptors, Interleukin-6/genetics ; Signal Transduction
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency.
Autorzy :: Werner-Klein M; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. .
Grujovic A; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.; Telexos GmbH, Weilheim, Germany.
Irlbeck C; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Obradović M; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.; Wellmera AG, Basel, Switzerland.
Hoffmann M; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Koerkel-Qu H; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Lu X; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Treitschke S; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Köstler C; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Botteron C; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Weidele K; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Werno C; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Polzer B; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Kirsch S; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Gužvić M; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Warfsmann J; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Honarnejad K; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Czyz Z; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Feliciello G; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany.
Blochberger I; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Grunewald S; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Schneider E; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Haunschild G; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Patwary N; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Guetter S; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Huber S; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany.
Rack B; Department OB&GYN and CCCLMU, Breast Center, LMU University Hospital, 80337, Munich, Germany.; Department of Gynecology, Ulm University Hospital, Ulm, Germany.
Harbeck N; Department OB&GYN and CCCLMU, Breast Center, LMU University Hospital, 80337, Munich, Germany.
Buchholz S; Clinic of Gynecology and Obstetrics, University Medical Center Regensburg, 93053, Regensburg, Germany.
Rümmele P; Department of Pathology, University of Regensburg, 93053, Regensburg, Germany.; Institute of Pathology, University Hospital, Friedrich-Alexander-University Erlangen-Nürnberg, 91054, Erlangen, Germany.
Heine N; University Center of Plastic-, Aesthetic, Hand- and Reconstructive Surgery, University of Regensburg, Regensburg, Germany.
Rose-John S; Institute of Biochemistry, Christian-Albrechts-Universität Kiel, Kiel, Germany.
Klein CA; Experimental Medicine and Therapy Research, University of Regensburg, Regensburg, Germany. .; Division of Personalized Tumour Therapy, Fraunhofer Institute for Toxicology and Experimental Medicine, 93053, Regensburg, Germany. .; Pokaż więcej
Źródło :: Nature communications [Nat Commun] 2020 Oct 05; Vol. 11 (1), pp. 4977. Date of Electronic Publication: 2020 Oct 05.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Signal Transduction*
Interleukin-6/*metabolism
Neoplastic Stem Cells/*metabolism
Neoplastic Stem Cells/*pathology
Bone Marrow/pathology ; Breast/cytology ; Breast Neoplasms/pathology ; Class I Phosphatidylinositol 3-Kinases/genetics ; Class I Phosphatidylinositol 3-Kinases/metabolism ; Cytokine Receptor gp130/metabolism ; Epithelial Cells/metabolism ; Epithelial Cells/pathology ; Female ; Humans ; Interleukin-6/genetics ; Mutation ; Neoplasm Metastasis/genetics ; Receptors, Interleukin-6/deficiency ; Receptors, Interleukin-6/metabolism ; Stromal Cells/metabolism ; Tumor Microenvironment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Autorzy :: Kang S; Department of Immune Regulation, Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan.
Tanaka T; Medical Affairs Bureau, Osaka Habikino Medical Center, Osaka 583-8588, Japan.
Inoue H; Department of Immune Regulation, Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan.
Ono C; Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.
Hashimoto S; Department of Clinical Laboratory, Osaka Habikino Medical Center, Osaka 583-8588, Japan.
Kioi Y; Department of Immune Regulation, Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan.
Matsumoto H; Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Matsuura H; Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Matsubara T; Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Shimizu K; Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Ogura H; Department of Traumatology and Acute Critical Medicine, Osaka University Graduate School of Medicine, Osaka University, Suita, Osaka 565-0871, Japan.
Matsuura Y; Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.
Kishimoto T; Department of Immune Regulation, Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan; .; Pokaż więcej
Źródło :: Proceedings of the National Academy of Sciences of the United States of America [Proc Natl Acad Sci U S A] 2020 Sep 08; Vol. 117 (36), pp. 22351-22356. Date of Electronic Publication: 2020 Aug 21.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Signal Transduction*
Cytokine Release Syndrome/*metabolism
Endothelial Cells/*metabolism
Interleukin-6/*metabolism
Plasminogen Activator Inhibitor 1/*metabolism
Adult ; Aged ; Antibodies, Monoclonal, Humanized/therapeutic use ; Betacoronavirus ; Burns/metabolism ; Burns/pathology ; COVID-19 ; Cells, Cultured ; Coronavirus Infections/drug therapy ; Coronavirus Infections/metabolism ; Coronavirus Infections/pathology ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/pathology ; Cytokines/blood ; Cytokines/metabolism ; Endothelial Cells/drug effects ; Female ; Humans ; Inflammation ; Interleukin-6/blood ; Male ; Middle Aged ; Pandemics ; Plasminogen Activator Inhibitor 1/blood ; Pneumonia, Viral/drug therapy ; Pneumonia, Viral/metabolism ; Pneumonia, Viral/pathology ; Receptors, Interleukin-6/antagonists & inhibitors ; Receptors, Interleukin-6/metabolism ; Respiratory Distress Syndrome/metabolism ; Respiratory Distress Syndrome/pathology ; SARS-CoV-2 ; Sepsis/metabolism ; Sepsis/pathology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Tocilizumab use in patients with moderate to severe COVID-19: A retrospective cohort study.
Autorzy :: Chilimuri S; Department of Medicine, Bronxcare Health System, Affiliated with Icahn School of Medicine at Mount Sinai, Bronx, NY, USA.
Sun H; Department of Medicine, Bronxcare Health System, Affiliated with Icahn School of Medicine at Mount Sinai, Bronx, NY, USA.
Alemam A; Department of Medicine, Bronxcare Health System, Affiliated with Icahn School of Medicine at Mount Sinai, Bronx, NY, USA.
Kang KS; Department of Pharmacy, Bronxcare Health System, Affiliated with Icahn School of Medicine at Mount Sinai, Bronx, NY, USA.
Lao P; Department of Pharmacy, Bronxcare Health System, Affiliated with Icahn School of Medicine at Mount Sinai, Bronx, NY, USA.
Mantri N; Department of Medicine, Bronxcare Health System, Affiliated with Icahn School of Medicine at Mount Sinai, Bronx, NY, USA.
Schiller L; Department of Pharmacy, Bronxcare Health System, Affiliated with Icahn School of Medicine at Mount Sinai, Bronx, NY, USA.
Sharabun M; Department of Pharmacy, Bronxcare Health System, Affiliated with Icahn School of Medicine at Mount Sinai, Bronx, NY, USA.
Shehi E; Department of Medicine, Bronxcare Health System, Affiliated with Icahn School of Medicine at Mount Sinai, Bronx, NY, USA.
Tejada J; Department of Medicine, Bronxcare Health System, Affiliated with Icahn School of Medicine at Mount Sinai, Bronx, NY, USA.
Yugay A; Department of Medicine, Bronxcare Health System, Affiliated with Icahn School of Medicine at Mount Sinai, Bronx, NY, USA.
Nayudu SK; Department of Medicine, Bronxcare Health System, Affiliated with Icahn School of Medicine at Mount Sinai, Bronx, NY, USA.; Pokaż więcej
Źródło :: Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2021 Apr; Vol. 46 (2), pp. 440-446. Date of Electronic Publication: 2020 Oct 24.
Typ publikacji :: Journal Article
MeSH Terms :: Antibodies, Monoclonal, Humanized*/administration & dosage
Antibodies, Monoclonal, Humanized*/adverse effects
COVID-19*/diagnosis
COVID-19*/drug therapy
COVID-19*/immunology
COVID-19*/mortality
Cytokine Release Syndrome*/blood
Cytokine Release Syndrome*/etiology
Interleukin-6*/antagonists & inhibitors
Interleukin-6*/blood
Respiration, Artificial*/methods
Respiration, Artificial*/statistics & numerical data
SARS-CoV-2*/isolation & purification
Correlation of Data ; Female ; Hospital Mortality ; Humans ; Immunologic Factors/administration & dosage ; Immunologic Factors/adverse effects ; Male ; Middle Aged ; Multiple Organ Failure/etiology ; Multiple Organ Failure/prevention & control ; New York City/epidemiology ; Retrospective Studies ; Treatment Outcome
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Preemptive interleukin-6 blockade in patients with COVID-19.
Autorzy :: Guillén L; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Padilla S; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Fernández M; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Agulló V; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
García JA; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Telenti G; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
García-Abellán J; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Botella Á; Infectious Diseases Unit, Hospital General Universitario de Elche, Camí de la Almazara S/N, Elche, 03203, Alicante, Spain.
Gutiérrez F; Clinical Medicine Department, Universidad Miguel Hernández, Ctra. de Valencia (N-322), Km 87, 03550, San Juan de Alicante, Spain. .; Universidad Miguel Hernández, Avda de la Universidad S/N, Elche, 03202, Alicante, Spain. .
Masiá M; Clinical Medicine Department, Universidad Miguel Hernández, Ctra. de Valencia (N-322), Km 87, 03550, San Juan de Alicante, Spain. .; Universidad Miguel Hernández, Avda de la Universidad S/N, Elche, 03202, Alicante, Spain. .; Pokaż więcej
Źródło :: Scientific reports [Sci Rep] 2020 Oct 08; Vol. 10 (1), pp. 16826. Date of Electronic Publication: 2020 Oct 08.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Betacoronavirus*
Organ Dysfunction Scores*
Antibodies, Monoclonal, Humanized/*pharmacology
Antibodies, Monoclonal, Humanized/*therapeutic use
Coronavirus Infections/*drug therapy
Pneumonia, Viral/*drug therapy
Receptors, Interleukin-6/*antagonists & inhibitors
Aged ; Aged, 80 and over ; Antibodies, Monoclonal, Humanized/adverse effects ; Biomarkers/blood ; C-Reactive Protein/analysis ; COVID-19 ; Coronavirus Infections/epidemiology ; Coronavirus Infections/virology ; Female ; Follow-Up Studies ; Humans ; Interleukin-6/blood ; Lymphocyte Count ; Lymphocytes ; Male ; Middle Aged ; Neutrophils ; Pandemics ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/virology ; SARS-CoV-2 ; Spain/epidemiology ; Treatment Outcome
SCR Protocol :: COVID-19 drug treatment
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 16 16.

Tytuł :: Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.
Autorzy :: Della-Torre E; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy .; Università Vita-Salute San Raffaele, Milan, Italy.
Campochiaro C; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy.; Università Vita-Salute San Raffaele, Milan, Italy.
Cavalli G; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy.; Università Vita-Salute San Raffaele, Milan, Italy.
De Luca G; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy.; Università Vita-Salute San Raffaele, Milan, Italy.
Napolitano A; Università Vita-Salute San Raffaele, Milan, Italy.; Clinical and Experimental Radiology Unit, Experimental Imaging Center, San Raffaele Hospital, Milan, Italy.
La Marca S; Università Vita-Salute San Raffaele, Milan, Italy.; Clinical and Experimental Radiology Unit, Experimental Imaging Center, San Raffaele Hospital, Milan, Italy.
Boffini N; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy.
Da Prat V; General Medicine and Advanced Care Unit, San Raffaele Hospital, Milan, Italy.
Di Terlizzi G; General Medicine and Advanced Care Unit, San Raffaele Hospital, Milan, Italy.
Lanzillotta M; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy.; Università Vita-Salute San Raffaele, Milan, Italy.
Rovere Querini P; Università Vita-Salute San Raffaele, Milan, Italy.; Internal Medicine, Diabetes & Endocrinology Unit, San Raffaele Hospital, Milan, Italy.
Ruggeri A; Hematology and Bone Marrow Transplant Unit, San Raffaele Hospital, Milan, Italy.
Landoni G; Università Vita-Salute San Raffaele, Milan, Italy.; Department of Anesthesia and Intensive Care, San Raffaele Hospital, Milan, Italy.
Tresoldi M; General Medicine and Advanced Care Unit, San Raffaele Hospital, Milan, Italy.
Ciceri F; Università Vita-Salute San Raffaele, Milan, Italy.; Hematology and Bone Marrow Transplant Unit, San Raffaele Hospital, Milan, Italy.
Zangrillo A; Università Vita-Salute San Raffaele, Milan, Italy.; Department of Anesthesia and Intensive Care, San Raffaele Hospital, Milan, Italy.
De Cobelli F; Università Vita-Salute San Raffaele, Milan, Italy.; Clinical and Experimental Radiology Unit, Experimental Imaging Center, San Raffaele Hospital, Milan, Italy.
Dagna L; Unit of Immunology, Rheumatology, Allergy, and Rare Diseases, San Raffaele Hospital, Milano, Lombardia, Italy .; Università Vita-Salute San Raffaele, Milan, Italy.; Pokaż więcej
Corporate Authors :: SARI-RAF Study Group
SARI-RAF Study Group members
Źródło :: Annals of the rheumatic diseases [Ann Rheum Dis] 2020 Oct; Vol. 79 (10), pp. 1277-1285. Date of Electronic Publication: 2020 Jul 03.
Typ publikacji :: Journal Article; Observational Study
MeSH Terms :: Antibodies, Monoclonal, Humanized/*therapeutic use
C-Reactive Protein/*immunology
Coronavirus Infections/*drug therapy
Inflammation/*immunology
Interleukin-6/*immunology
Pneumonia, Viral/*drug therapy
Administration, Intravenous ; Anti-Bacterial Agents/therapeutic use ; Antiviral Agents/therapeutic use ; Azithromycin/therapeutic use ; Bacteremia/epidemiology ; Betacoronavirus ; COVID-19 ; Cohort Studies ; Coinfection/epidemiology ; Coronavirus Infections/diagnostic imaging ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Drug Combinations ; Enzyme Inhibitors/therapeutic use ; Female ; Humans ; Hydroxychloroquine/therapeutic use ; Italy ; Lopinavir/therapeutic use ; Lung/diagnostic imaging ; Male ; Middle Aged ; Noninvasive Ventilation ; Oxygen Inhalation Therapy ; Pandemics ; Pneumonia, Viral/diagnostic imaging ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; Proportional Hazards Models ; Receptors, Interleukin-6/antagonists & inhibitors ; Ritonavir/therapeutic use ; SARS-CoV-2 ; Severity of Illness Index ; Time Factors ; Tomography, X-Ray Computed ; Treatment Outcome
SCR Protocol :: COVID-19 drug treatment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy.
Autorzy :: Montesarchio V; Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.
Parrela R; Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.
Iommelli C; Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.
Bianco A; Department of Medical Oncology, Azienda Ospedaliera dei Colli-Monaldi Hospital, Napoli, Italy.
Manzillo E; Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.
Fraganza F; Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
Palumbo C; Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
Rea G; Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
Murino P; Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
De Rosa R; Critical Area Department, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
Atripaldi L; Department of Health Services, Azienda Ospedaliera dei Colli-Cotugno and Monaldi Hospital, Napoli, Italy.
D'Abbraccio M; Department of Infectious Diseases and Infectious Diseases Emergencies, Azienda Ospedaliera dei Colli-Cotugno Hospital, Napoli, Italy.
Curvietto M; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Mallardo D; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Celentano E; Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Grimaldi AM; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Palla M; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Trojaniello C; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Vitale MG; Department of Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Campania, Italy.
Million-Weaver SL; Independent Investigator, Madison, Wisconsin, USA.
Ascierto PA; Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy .; Pokaż więcej
Źródło :: Journal for immunotherapy of cancer [J Immunother Cancer] 2020 Aug; Vol. 8 (2).
Typ publikacji :: Journal Article
MeSH Terms :: Antibodies, Monoclonal, Humanized/*therapeutic use
Biomarkers, Pharmacological/*blood
Coronavirus Infections/*drug therapy
Interleukin-6/*blood
Pneumonia, Viral/*drug therapy
Aged ; Antiviral Agents/therapeutic use ; COVID-19 ; Coronavirus Infections/complications ; Coronavirus Infections/diagnostic imaging ; Female ; Humans ; Italy ; Lymphocyte Count ; Male ; Middle Aged ; Neutrophils ; Pandemics ; Pneumonia, Viral/complications ; Pneumonia, Viral/diagnostic imaging ; Receptors, Interleukin-6/antagonists & inhibitors ; Retrospective Studies ; Treatment Outcome
SCR Protocol :: COVID-19 drug treatment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19.
Autorzy :: Saha A; Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal, India.
Sharma AR; Institute for Skeletal Aging and Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, Gangwon-do, South Korea.
Bhattacharya M; Department of Zoology, Fakir Mohan University, Balasore, Odisha, India.
Sharma G; Neuropsychopharmacology and Toxicology Program, College of Pharmacy, Kangwon National University, Gangwon-do, South Korea.
Lee SS; Institute for Skeletal Aging and Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, Gangwon-do, South Korea.
Chakraborty C; Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal, India. Electronic address: .; Pokaż więcej
Źródło :: Archives of medical research [Arch Med Res] 2020 Aug; Vol. 51 (6), pp. 595-597. Date of Electronic Publication: 2020 May 21.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :: Antibodies, Monoclonal, Humanized/*therapeutic use
Coronavirus Infections/*drug therapy
Cytokine Release Syndrome/*drug therapy
Pneumonia, Viral/*drug therapy
Receptors, Interleukin-6/*antagonists & inhibitors
Betacoronavirus ; COVID-19 ; Humans ; Interleukin-6/immunology ; Pandemics ; Protein Binding ; SARS-CoV-2 ; Signal Transduction
SCR Protocol :: COVID-19 drug treatment
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks.
Autorzy :: Crisafulli S; Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Policlinico Universitario 'G. Martino', Via Consolare Valeria 1, 98125, Messina, Italy.
Isgrò V; Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Policlinico Universitario 'G. Martino', Via Consolare Valeria 1, 98125, Messina, Italy.
La Corte L; Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina, Italy.
Atzeni F; Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina, Italy.
Trifirò G; Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Policlinico Universitario 'G. Martino', Via Consolare Valeria 1, 98125, Messina, Italy. .; Pokaż więcej
Źródło :: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy [BioDrugs] 2020 Aug; Vol. 34 (4), pp. 415-422.
Typ publikacji :: Journal Article; Review
MeSH Terms :: Coronavirus Infections/*therapy
Interleukin-6/*antagonists & inhibitors
Pneumonia, Viral/*therapy
Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; COVID-19 ; Coronavirus Infections/metabolism ; Coronavirus Infections/pathology ; Humans ; Pandemics ; Pneumonia, Viral/metabolism ; Pneumonia, Viral/pathology ; Receptors, Interleukin-6/antagonists & inhibitors ; Risk Assessment ; Safety
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Satralizumab: an interleukin-6 (IL-6) receptor antagonist for the treatment of neuromyelitis optica spectrum disorders.
Autorzy :: Paton DM; Professor Emeritus of Pharmacology, University of Auckland, Auckland, New Zealand and Professor Emeritus of Oral Biology, University of Alberta, Edmonton, Alberta, Canada. .; Pokaż więcej
Źródło :: Drugs of today (Barcelona, Spain : 1998) [Drugs Today (Barc)] 2021 Mar; Vol. 57 (3), pp. 209-218.
Typ publikacji :: Journal Article
MeSH Terms :: Interleukin-6*
Neuromyelitis Optica*/drug therapy
Adult ; Antibodies, Monoclonal, Humanized/therapeutic use ; Aquaporin 4 ; Female ; Humans
: Czasopismo naukowe

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Interleukin-6"" wg kryterium: Temat

Aktywne filtry:

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język